Replies to post #27494 on Revive Therapeutics Ltd (RVVTF)

[Vmoore]

There’s going to be multiple oral covid therapeutics. The data will be the differentiator and drive market value.

We haven’t seen data yet, but the science behind bucillamine is superior to any other phase 3 drug that’s close behind us.